GILD vs PFE vs AMGN
161 measures in 16 categories, one definition each, computed from filings and market data.
GILD43.8
Gilead Sciences, Inc.
Healthcare · Drug Manufacturers - General
$156.19 −0.75%$193.7B mkt cap
Score DNA
PFE46.1
Pfizer Inc.
Healthcare · Drug Manufacturers - General
$29.58 +0.44%$168.6B mkt cap
Score DNA
AMGN67.3
Amgen Inc.
Healthcare · Drug Manufacturers - General
$432.49 −0.35%$233.8B mkt cap
Score DNA
Price, rebased to 100 three years ago
GILD PFE AMGN · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| Insider open-market buys, 180d | 0 | 3 | 0 |
| Insider $ bought, 180d | — | $2.96M | — |
| Congress purchases, 180d | 5 | 3 | 6 |
| Last Congress purchase | 2026-05-06 | 2026-09-25 | 2026-09-22 |
| 13F net change in holders | −32 | −119 | +19 |
| ETFs adding shares, 30d | 1,962 | 1,403 | 1,757 |
| ETFs trimming, 30d | 1,592 | 1,166 | 1,417 |
| Net ETF funds, 30d | +370 | +237 | +340 |
Valuation
16 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| P/E (TTM) | — | 38.9x
60th
|
26.7x
40th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | — | — | 10.09
100th
|
| Price / sales | 6.4x
82nd
|
2.6x
18th
|
6.1x
64th
|
| Price / book | 16.4x
80th
|
2.0x
10th
|
20.0x
90th
|
| Price / tangible book | — | — | — |
| Price / free cash flow | 14.7x
27th
|
15.3x
36th
|
23.0x
64th
|
| Price / operating cash flow | 14.3x
36th
|
12.6x
27th
|
18.7x
73rd
|
| Enterprise value | $216.7B
27th
|
$220.1B
36th
|
$277.1B
45th
|
| EV / sales | 7.1x
73rd
|
3.5x
18th
|
7.3x
82nd
|
| EV / EBITDA | 162.5x
100th
|
16.9x
45th
|
15.7x
36th
|
| EV / EBIT | — | 31.9x
60th
|
21.4x
40th
|
| EV / free cash flow | 16.4x
18th
|
20.0x
27th
|
27.2x
64th
|
| Earnings yield | -1.7%
0th
|
2.6%
45th
|
3.7%
64th
|
| FCF yield | 6.8%
73rd
|
6.5%
64th
|
4.4%
36th
|
| Operating cash flow yield | 7.0%
64th
|
7.9%
73rd
|
5.3%
27th
|
| Graham number (per share) | — | $15.99
11th
|
$88.14
78th
|
Profitability (TTM)
12 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| Gross margin | 79.6%
91st
|
71.3%
36th
|
72.7%
55th
|
| EBITDA margin | 4.4%
0th
|
20.5%
9th
|
46.2%
91st
|
| Operating margin | -4.9%
0th
|
25.1%
45th
|
33.2%
91st
|
| EBIT margin | -4.7%
0th
|
10.8%
9th
|
34.0%
91st
|
| Net margin | -10.6%
0th
|
6.8%
27th
|
22.9%
82nd
|
| NOPAT margin | -3.9%
0th
|
26.1%
82nd
|
28.2%
91st
|
| FCF margin | 43.3%
100th
|
17.2%
18th
|
26.7%
64th
|
| Operating cash flow margin | 44.5%
100th
|
21.0%
9th
|
32.7%
73rd
|
| R&D / revenue | 19.9%
45th
|
20.1%
64th
|
20.0%
55th
|
| SG&A / revenue | 21.2%
45th
|
20.9%
36th
|
18.4%
27th
|
| Stock comp / revenue | 1.5%
91st
|
1.1%
64th
|
1.0%
27th
|
| Effective tax rate | 21.0%
64th
|
-3.9%
0th
|
15.0%
18th
|
Returns on capital
11 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| ROE (on average equity) | -20.6%
0th
|
5.0%
20th
|
91.5%
90th
|
| ROA | -6.2%
0th
|
2.1%
18th
|
9.5%
64th
|
| ROIC | -3.4%
0th
|
12.1%
36th
|
19.5%
82nd
|
| ROCE | -3.7%
0th
|
4.1%
18th
|
18.5%
73rd
|
| Return on tangible assets | -2.7%
0th
|
3.4%
9th
|
14.1%
73rd
|
| Cash ROIC (OCF / invested capital) | 38.8%
100th
|
9.8%
9th
|
22.7%
64th
|
| Gross profitability (GP / assets) | 49.1%
100th
|
22.6%
9th
|
29.0%
27th
|
| ROIC, 3-yr average | 3.5%
0th
|
5.9%
36th
|
13.9%
73rd
|
| ROIC, 5-yr average | 6.9%
0th
|
12.1%
44th
|
21.5%
78th
|
| ROE, 5-yr average | 11.4%
11th
|
13.9%
33rd
|
121.3%
100th
|
| Incremental ROIC | 94.2%
82nd
|
-257.4%
9th
|
95.6%
91st
|
Growth
17 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| Revenue growth (TTM YoY) | 5.5%
55th
|
-0.2%
18th
|
9.2%
82nd
|
| Revenue growth (QoQ) | 12.1%
64th
|
4.0%
18th
|
16.7%
100th
|
| Revenue CAGR, 3 yr | 3.6%
36th
|
-6.7%
0th
|
12.8%
91st
|
| Revenue CAGR, 5 yr | 2.7%
36th
|
2.9%
45th
|
8.4%
73rd
|
| Gross profit CAGR, 3 yr | 3.7%
27th
|
-3.1%
18th
|
12.0%
82nd
|
| Operating income CAGR, 3 yr | — | -12.8%
10th
|
10.0%
50th
|
| Net income growth (TTM YoY) | — | -59.7%
20th
|
32.1%
70th
|
| Net income CAGR, 3 yr | — | -41.4%
0th
|
3.1%
50th
|
| EPS growth (TTM YoY) | — | -59.6%
20th
|
31.4%
60th
|
| EPS CAGR, 3 yr | — | -41.3%
0th
|
2.7%
50th
|
| EPS CAGR, 5 yr | — | -19.8%
0th
|
10.0%
67th
|
| FCF growth (TTM YoY) | 40.9%
90th
|
-11.7%
10th
|
-4.1%
30th
|
| FCF CAGR, 3 yr | 13.9%
55th
|
1.0%
9th
|
1.7%
18th
|
| Operating cash flow CAGR, 3 yr | 12.5%
82nd
|
-2.7%
9th
|
4.9%
36th
|
| Book value CAGR, 3 yr | -17.3%
0th
|
-4.8%
22nd
|
19.4%
78th
|
| Dividend CAGR, 3 yr | 1.3%
20th
|
0.6%
10th
|
1.6%
30th
|
| Sustainable growth rate | — | -6.3%
11th
|
36.2%
89th
|
Margin history & stability
7 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| Gross margin, 3-yr average | 77.9%
82nd
|
62.6%
9th
|
66.8%
27th
|
| Operating margin, 3-yr average | 10.7%
0th
|
19.5%
18th
|
25.5%
73rd
|
| Net margin, 3-yr average | 5.0%
0th
|
6.3%
18th
|
17.3%
64th
|
| FCF margin, 3-yr average | 33.5%
100th
|
15.1%
18th
|
24.9%
64th
|
| Revenue stability (0-1) | 0.88
64th
|
0.02
0th
|
0.90
73rd
|
| Earnings stability (0-1) | 0.35
73rd
|
0.33
64th
|
0.08
18th
|
| Margin stability (0-1) | 0.98
91st
|
0.87
0th
|
0.92
27th
|
Liquidity (latest quarter)
7 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| Cash & short-term investments | $3.2B
18th
|
$11.7B
82nd
|
$14.0B
91st
|
| Net cash (− = net debt) | −$23.1B
82nd
|
−$51.5B
9th
|
−$43.3B
36th
|
| Working capital | $2.9B
36th
|
$8.7B
64th
|
$9.5B
82nd
|
| Current ratio | 1.27
36th
|
1.27
45th
|
1.37
73rd
|
| Quick ratio | 1.09
55th
|
0.96
36th
|
1.13
73rd
|
| Cash ratio (cash + ST investments / current liabilities) | 0.29
45th
|
0.36
64th
|
0.55
91st
|
| Defensive interval (days) | 117 days
0th
|
300 days
55th
|
587 days
100th
|
Leverage & solvency (latest quarter)
13 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| Total debt | $26.2B
18th
|
$63.2B
91st
|
$57.3B
82nd
|
| Debt / equity | 2.22
80th
|
0.74
30th
|
4.90
90th
|
| Net debt / equity | 1.95
80th
|
0.60
30th
|
3.71
90th
|
| Debt / assets | 53.2%
82nd
|
31.4%
27th
|
59.9%
91st
|
| Debt / capital | 68.9%
80th
|
42.6%
30th
|
83.1%
90th
|
| Debt / EBITDA | 19.67
100th
|
4.84
82nd
|
3.25
45th
|
| Net debt / EBITDA | 17.29
100th
|
3.94
82nd
|
2.46
45th
|
| Interest coverage (EBIT / interest) | −1.4x
0th
|
2.6x
18th
|
4.9x
45th
|
| Cash interest coverage | 13.6x
73rd
|
5.0x
18th
|
4.7x
9th
|
| Debt payback (years of OCF) | 1.9 yrs
0th
|
4.7 yrs
91st
|
4.6 yrs
82nd
|
| Liabilities / assets | 76.2%
73rd
|
57.5%
18th
|
87.8%
82nd
|
| IS credit model rating | BB+ | BB | BB |
| Implied credit spread (bps) | 400
64th
|
475
73rd
|
475
73rd
|
Efficiency
11 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| Asset turnover | 0.58
91st
|
0.31
0th
|
0.42
18th
|
| Fixed asset turnover | 5.22
82nd
|
3.35
27th
|
4.46
55th
|
| Inventory turnover | 3.3
82nd
|
1.7
36th
|
1.6
18th
|
| Receivables turnover | 6.2
100th
|
5.2
64th
|
4.0
0th
|
| Days sales outstanding | 59 days
0th
|
70 days
36th
|
91 days
100th
|
| Days inventory outstanding | 111 days
18th
|
216 days
64th
|
224 days
82nd
|
| Days payables outstanding | 37 days
0th
|
97 days
27th
|
404 days
82nd
|
| Cash conversion cycle (days) | 133 days
73rd
|
189 days
82nd
|
−89 days
18th
|
| Capex / revenue | 1.2%
10th
|
3.8%
30th
|
6.0%
80th
|
| Capex / depreciation | 0.13
10th
|
0.39
20th
|
0.49
50th
|
| Operating expense ratio | 213.0%
100th
|
41.5%
55th
|
37.1%
27th
|
Cash flow & earnings quality
7 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| Operating cash flow / net income | — | 3.09
70th
|
1.43
40th
|
| FCF / net income | — | 2.53
70th
|
1.16
30th
|
| FCF / operating cash flow | 97.4%
90th
|
82.0%
60th
|
81.5%
50th
|
| Capex / operating cash flow | 2.6%
10th
|
18.0%
40th
|
18.5%
50th
|
| Accruals ratio | -32.0%
0th
|
-4.5%
45th
|
-4.1%
55th
|
| Sloan accruals ratio | -6.4%
18th
|
-1.7%
55th
|
-1.6%
73rd
|
| Earnings quality score (0-1) | — | 1.00
30th
|
1.00
30th
|
Scores & forensic checks
15 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| IS score | 44
9th
|
46
18th
|
67
73rd
|
| IS profitability | 20
0th
|
45
27th
|
88
73rd
|
| IS growth | 37
36th
|
20
9th
|
74
82nd
|
| IS value | 27
0th
|
49
82nd
|
43
55th
|
| IS momentum | 38
0th
|
55
27th
|
91
82nd
|
| IS risk (safety) | 80
55th
|
50
9th
|
50
9th
|
| IS quality | 32
0th
|
73
55th
|
69
36th
|
| IS balance sheet | 20
0th
|
43
36th
|
41
27th
|
| IS earnings quality | 26
0th
|
71
82nd
|
67
27th
|
| IS cash flow | 78
91st
|
59
9th
|
68
55th
|
| Piotroski F-score (0-9) | 5
18th
|
7
45th
|
8
73rd
|
| Altman Z-score | 3.2
55th
|
2.0
9th
|
2.0
18th
|
| Beneish M-score | −4.14
0th
|
−2.72
45th
|
−2.56
64th
|
| Ohlson O-score | −6.75
91st
|
−8.49
27th
|
−6.96
82nd
|
| IS credit score | 47
36th
|
43
18th
|
44
27th
|
Size (TTM)
8 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| Market cap | $193.7B
36th
|
$168.6B
27th
|
$233.8B
45th
|
| Revenue | $30.5B
18th
|
$63.7B
64th
|
$38.1B
27th
|
| EBITDA | $1.3B
9th
|
$13.1B
27th
|
$17.6B
55th
|
| Net income | −$3.2B
0th
|
$4.3B
36th
|
$8.7B
55th
|
| Free cash flow | $13.2B
55th
|
$11.0B
36th
|
$10.2B
27th
|
| Total assets | $49.4B
18th
|
$201.1B
100th
|
$95.6B
36th
|
| Shareholders' equity | $11.8B
27th
|
$85.2B
100th
|
$11.7B
18th
|
| Employees | 17,000
18th
|
75,000
73rd
|
31,500
27th
|
Price performance
9 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| 1 day | −0.8% | +0.4% | −0.3% |
| 1 week | +3.3% | +4.6% | +4.2% |
| 1 month | +3.5% | +7.0% | +13.9% |
| 3 months | +17.2% | +21.6% | +19.5% |
| 6 months | +13.5% | +7.3% | +23.4% |
| Year to date | +28.4% | +19.4% | +34.7% |
| 1 year | +32.9% | +23.4% | +49.5% |
| 3 years, cumulative | +119.2% | +3.0% | +66.8% |
| 5 years, cumulative | +169.4% | −13.7% | +141.8% |
Technicals
4 measures| Measure | GILD | PFE | AMGN |
|---|---|---|---|
| RSI 14 | 63.5 | 69.7 | 62.5 |
| From 52-week high | −2.7% | −1.0% | −3.2% |
| From 52-week low | +37.9% | +25.2% | +54.3% |
| Beta | 0.33 | 0.28 | 0.41 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17